SIRPA and neoplasm: CD47 × CD19 or CD20 bispecific antibodies are able to improve tumor lysis by effector cells in a targeted fashion by selectively blocking the CD47-SIRPα interaction on malignant cells expressing a specific tumor-associated antigen, thus improving efficacy and minimizing toxicity[105].